Table 3 Primary and secondary endpoint rates according to high-sensitivity C-reactive protein (hs-CRP) quartiles in the overall study population and in patients with and without diabetes mellitus
| Â | Hs-CRP quartiles | ||||
|---|---|---|---|---|---|
1 (< 1.45 mg/L) | 2 (1.45-3.71 mg/L) | 3 (3.72-12.29 mg/L) | 4 (> 12.30 mg/L) | P for trend | |
In-hospital clinical combined endpoint, n (%) | |||||
 Overall population | 35 (7%) | 44 (9%) | 68 (13%) | 114 (22%) | < 0.0001 |
 Patients with diabetes mellitus | 14 (14%) | 11 (9%) | 29 (21%) | 51 (27%) | 0.0001 |
 Patients without diabetes mellitus | 21 (5%) | 33 (8%) | 39 (10%) | 63 (19%) | < 0.0001 |
Two-year mortality, n (%) | |||||
 Overall population | 25 (5%) | 36 (7%) | 49 (9%) | 88 (17%) | < 0.0001 |
 Patients with diabetes mellitus | 11 (11%) | 18 (15%) | 20 (15%) | 41 (22%) | 0.01 |
 Patients without diabetes mellitus | 15 (4%) | 18 (5%) | 29 (8%) | 47 (14%) | <0.0001 |